Evaluation of efficacy of moxifloxacin (0.5%) in the treatment of non-perforated bacterial corneal ulcers

ISRCTN ISRCTN10323655
DOI https://doi.org/10.1186/ISRCTN10323655
Secondary identifying numbers OP-19/07.09.2009
Submission date
30/06/2010
Registration date
11/08/2010
Last edited
09/09/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Namrata Sharma
Scientific

Rajendra Prasad Centre for Ophthalmic Sciences
All India Institute of Medical Sciences (AIIMS)
Ansari Nagar
New Delhi
110029
India

Phone +91 (0)11 26593144
Email namrata103@hotmail.com

Study information

Study designProspective randomised controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use contact details below to request a patient information sheet
Scientific titleEvaluation of efficacy of moxifloxacin (0.5%) in the treatment of non-perforated bacterial corneal ulcers: a randomised controlled trial
Study objectivesThe use of fortified intensive antibiotics has practical limitations related to availability and cost. The effectiveness of multiple fortified antibiotics is limited further by variability in shelf life and the dissipation of 1 agent if a second agent is applied shortly thereafter. The use of multiple antibiotics simultaneously and with frequent dosing may result in added toxicity and damage to the ocular surface epithelium, thereby impairing recovery.

Fluoroquinolones offer the advantages of good ocular penetration, demonstration of broad-spectrum efficacy, excellent safety profiles in ocular infections, and a distinct mode of resistance acquisition.

Moxifloxacin is a fourth-generation fluoroquinolone that exhibits a broad spectrum of bactericidal activity against both Gram-positive and Gram- negative bacterial pathogens, including staphylococci, S. pneumoniae, members of the family enterobacteriaceae, P. aeruginosa, H. influenzae, and Moraxella species. Moxifloxacin has also been shown to have superior activity compared with ciprofloxacin against quinolone resistant strains of S. aureus. Data also shows superior corneal and aqueous penetration of moxifloxacin and so higher therapeutic levels can be obtained, which should lead to more effective antimicrobials activity and hence better clinical outcomes.
Ethics approval(s)The All India Institute of Medical Sciences Ethics Committee approved on the 4th August 2009 (ref: P-09/2.03.2009 & AA-04/04.08.2009)
Health condition(s) or problem(s) studiedCorneal ulcer
InterventionDrug instillation protocol:
1. First 48 hours: 1 drop hourly, day and night
2. Day 3: 1 drop hourly by daya and every 2 hours at night
3. Days 4 - 5: 1 drop every 2 hours by day and every 4 hours by night
4. Days 6 - 7: 1 drop every 4 hours
5. Weeks 2 - 8: 1 drop every 6 hours and stopped when clinically appropriate

The total duration of treatment will be 8 weeks. Additional supportive treatment included vitamins, cycloplegic and antiglaucoma therapy if required. Any change of protocol, adverse event and surgical intervention was documented.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Moxifloxacin
Primary outcome measure1. Time to epithelialisation
2. Time to resolution of the infiltrates

All outcomes were measured on days 2, 4, 7, 14, 21 and at 3 months.
Secondary outcome measures1. Uncorrected Visual Acuity (UCVA)
2. Best Corrected Visual Acuity (BCVA)

All outcomes were measured on days 2, 4, 7, 14, 21 and at 3 months.
Overall study start date01/02/2009
Completion date01/02/2010

Eligibility

Participant type(s)Patient
Age groupNot Specified
SexBoth
Target number of participants150
Key inclusion criteriaNon-perforated bacterial corneal ulcers
Key exclusion criteria1. Known allergy to fluoroquinolones, aminoglycosides, penicillins,cephalosporins or benzalkoniun chloride
2. Patients with fungal, viral or acanthamoeba infection
3. Patients to be treated with subconjuctival injection(s) of antibiotic(s) and/or with systemic antimicrobials
4. Patients aged 16 - 65 years
5. Pregnant and lactating females
6. Any adverse effects or protocol violations
7. Perforated corneal ulcers
Date of first enrolment01/02/2009
Date of final enrolment01/02/2010

Locations

Countries of recruitment

  • India

Study participating centre

Rajendra Prasad Centre for Ophthalmic Sciences
New Delhi
110029
India

Sponsor information

Rajendra Prasad Centre for Ophthalmic Sciences (India)
Hospital/treatment centre

All India Institute of Medical Sciences (AIIMS)
Ansari Nagar
New Delhi
110029
India

Phone +91 (0)11 26593101
Email namrata103@hotmail.com
Website http://www.aiims.edu/rpcentre.htm
ROR logo "ROR" https://ror.org/02dwcqs71

Funders

Funder type

Research organisation

All India Institute of Medical Sciences (AIIMS) (India)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan